Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc.

Overview
Date Founded

2011

Headquarters

8000 Marina Boulevard, Suite 300, Brisbane, CA, 94005, USA

Type of Company

Public

Employees (Worldwide)

275

Industries

Pharmaceuticals
Hospitals & Patient Services
Hotels, Resorts, and Cruiselines
Medical Support Services
Biotechnology

Company Description

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Contact Data
Trying to get in touch with decision makers at Aimmune Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director, President & Chief Executive Officer

Chief Financial Officer & Corporate Secretary

General Counsel & Secretary

Chief Commercial Officer

Chief Medical Officer

Senior Vice President, Product & Portfolio Management

Vice President, Commercial Operations

Vice President-Clinical Operations

Vice President, Medical Affairs & Market Access

Consultant

Board of Directors

Partner at Qiming Venture Partners Ltd.

Former Chief Financial Officer at INAMED Corp.

Co-Founder at Longitude Capital Management Co. LLC

Chairman of the Board, President & Chief Executive Officer at Kala Pharmaceuticals, Inc.

Director, President & Chief Executive Officer at Aimmune Therapeutics, Inc.

Senior Vice President, Chief Medical Officer at Theravance Biopharma, Inc.

Chief Executive Officer at Nestlé Health Science SA

Partner at Aisling Capital

Paths to Aimmune Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Aimmune Therapeutics, Inc.
Owners & Shareholders
Details Hidden

PCM seeks to provide clients with consistently superior risk-adjusted rates of return through implementing event-driven strategies. Their investment strategies generally focus on an event or a catalyst that will move an equity price, an equity spread, a credit spread, or an implied volatility spread. Their investment strategies may include: merger arbitrage, catalyst-driven credit investing, special situation investing and distressed investing. Catalyst events may include mergers, acquisitions, spin-offs, carve-outs, tender offers, split-off exchange offers, share class spreads, re-organizations and corporate distress. PCM seeks to trade in all forms of the capital structure of companies involved in catalysts and events and to create the best risk/reward trade possible within the corporate capital structure. They attempt to limit risk through diversification and hedging. The firm may choose to take control positions in an attempt to create their own catalyst or event. In managing the fund’s portfolio, PCM relies on fundamental analysis supplemented by quantitative analytics and portfolio management techniques. They take both long and short positions for their clients in a broad range of public and private debt securities, equity securities, options, derivatives and credit derivatives (including credit default swaps), trade claims, bank debt participations and other instruments. PCM invests within and outside of the US, as well as in issuers in various stages of financial distress.

Details Hidden

Alpine Associates Management manages the investment portfolios of the Alpine Funds and the accounts of their other clients using several strategies. Their main strategies are merger arbitrage and long/short equity trading. Alpine also uses other strategies including convertible arbitrage and investing in bankruptcy and other credit opportunities. Alpine seeks to produce superior risk-adjusted returns with low volatility in all types of market environments.Alpine's long/short equity trading strategy involves the purchase and sale of actively traded common stocks. They also trades in stock index futures and other derivatives, options, preferred stocks, corporate and government bonds, swaps, other securities and financial instruments and currencies. Alpine may engage in pairs trading. A major part of this strategy involves the creation of synergistic positions in connection with Alpine's merger arbitrage and bankruptcy and other credit opportunities strategies. The firm seeks to capitalize on market dislocations caused by mergers and other corporate transactions and events. They also engage in general equity trading, using technical and fundamental analysis to identify stocks that are underpriced or overpriced relative to their peers or on an absolute basis.Alpine's merger arbitrage strategy focuses on the purchase of securities sought in cash tender offers, exchange offers, mergers or other extraordinary transactions, and the tendering or exchange of these securities for cash or new securities. When a new security is offered in exchange for a purchased security, Alpine simultaneously takes an offsetting short position that is covered with the new security when it is received. This strategy may involve purchasing or selling options, swaps and other derivative instruments to enhance returns or limit risk. Alpine's merger arbitrage strategy focuses on publicly announced transactions with definitive merger agreements.

Details Hidden

Magnetar Financial implements a variety of different strategies in managing private investment funds and separately managed accounts (SMAs) which designed to achieve attractive risk-adjusted rates of return. Some of the funds and SMAs employ a multi-strategy approach, utilizing a wide range of strategies across a range of geographies, while others focus on one or just a few strategies. It may hold both long and short positions in a broad range of securities, derivatives, and other assets. In executing their investment strategies, the funds and SMAs may enter into joint venture or co-investment arrangements, participate in pooled investment vehicles, invest with affiliated or unaffiliated advisors or managers, or make direct investments in operating entities. The firm’s main investment strategies are divided into the following categories: relative-value, event-driven, directional, hybrid and other investment strategies.

Recent Transactions
Details Hidden

Aimmune Therapeutics, Inc. issued USD Common Stock

Details Hidden

Aimmune Therapeutics, Inc. issued USD Common Stock

Details Hidden

Aimmune Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors
Underwriter

Advised onAimmune Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onAimmune Therapeutics, Inc. issued USD Common Stock

Auditor

Advised onAimmune Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onAimmune Therapeutics, Inc. issued USD Common Stock

Managing Director

Advised onAimmune Therapeutics, Inc. issued USD Common Stock

Global Co-Chair, Emerging Company Practice

Advised onAimmune Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Special Advisor

President & Chief Executive Officer at Sierra Oncology, Inc.

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Key Stats and Financials As of 2019
Market Capitalization
$2.25B
Total Enterprise Value
Earnings Per Share
Revenue
$0
EBITDA
$-246M
Investors
Details Hidden

Foresite Capital invests in public and private healthcare companies. The firm targets the companies in the fields of biopharmaceutical, biotechnology, drug/device combinations & medical devices, genomics, tools & data-science, healthcare services and pharmaceuticals. They are managing $3 billion assets.

Details Hidden

FMR may use a variety of methods of security analysis in managing client assets to select investments including fundamental analysis, quantitative analysis and cyclical analysis. They may also use general macro-economic analysis as a component of its security analysis methods. In addition to relying on public financial statement information, the firm may use extensive corporate visits and interviews with issuer management teams in conducting research. When it comes to the management of the client assets according to the investment objectives, FMR may use a variety of investment strategies including, but not limited to, investing in stocks and other public and private equity securities, bonds and other debt securities of all types and repurchase agreements for those securities, real estate related investments of all types, derivatives, currency spot and forward trading, other investment funds, including exchange traded funds and FMR’s or its affiliates’ central funds. They may also engage in securities lending to parties such as broker-dealers or other institutions.

Details Hidden

ACM manages the Adage Capital Partners Fund (ACP). The firm seeks to achieve its objective through stock selection based primarily on intra-industry fundamental analysis with a dedicated focus on intra-industry valuation methodologies. Primary research is a central component of their investment process. ACM utilizes a staff of portfolio managers and equity analysts dedicated to tracking specific sectors represented within the Index that utilize a stock valuation methodology designed for each specific sector in selecting the investments of ACP. The firm currently utilizes one non-industry specific analyst, focusing on risk arbitrage opportunities for ACP. They may employ additional analysts and/or portfolio managers in the future, focusing on non-industry specific methodologies for identifying investments for ACP, and in connection with such methodologies ACM may cause ACP engage in additional types of investments, such as leveraged trading and/or risk arbitrage or other event driven trading.

Suppliers
Archer Daniels Midland Co. Agriculture & Mills | Chicago, Illinois

Archer-Daniels-Midland Co. processes oilseeds, corn, wheat, cocoa and other agricultural commodities. The company operates through the following segments: Ag Services and Oilseeds, Carbohydrate Solutions and Nutrition. The Ag Services and Oilseeds segment includes activities related to the origination, merchandising, crushing, and further processing of oilseeds such as soybeans and soft seeds, such as cottonseed, sunflower seed, canola, rapeseed, and flaxseed into vegetable oils and protein meals. The Carbohydrate Solutions segment engages in corn wet milling and dry milling activities; and also converts corn into sweeteners, starches, and bioproducts. The Nutrition segment provides customer needs for food, beverages, health and wellness, and more. Archer-Daniels-Midland was founded in 1902 and is headquartered in Chicago, IL.

Post Holdings, Inc. Hotels, Resorts, and Cruiselines | St. Louis, MO

Corporate Profile Post is a leading manufacturer, marketer and distributor of branded ready-to-eat cereals in the United States and Canada. Post's products are manufactured through a flexible production platform consisting of four owned primary facilities and sold through a variety of channels such as grocery stores, mass merchandisers, club stores, and drug stores. Post has leveraged the strength of its brands, category expertise, and over a century of institutional knowledge to create a diverse portfolio of cereals that enhance the lives of consumers, bringing quality foods to the breakfast table since the company's founding in 1897. Post's portfolio of brands includes diverse offerings such as Honey Bunches of Oats®, Pebbles®, Post Selects®, Great Grains®, Spoon Size® Shredded Wheat, Post® Raisin Bran, Grape-Nuts®, and Honeycomb®. Post's common stock is listed on the New York Stock Exchange under the symbol "POST." For more information about Post, please visit www.postfoods.com.

Xencor, Inc. Biotechnology | Monrovia, CA

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Aimmune Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Aimmune Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Aimmune Therapeutics, Inc..